⌕
Taysha Gene Therapies · TSHA · Nasdaq
Tenet 58 · Mixed
Compare
$4.00−1.48%At closeTenet 58 · Mixed
$4.00−0.06 (−1.48%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Taysha Gene Therapies (TSHA) Institutional Ownership

13F filers reported holding 39.2% of Taysha Gene Therapies (TSHA) shares as of Sep 30, 2026, across 135 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
39.2%
Sep 30, 2026
13F filers
135
quarter ended Sep 30, 2026
13F value
$622.1M
127.7M shares
Quarter's fund flow
Mild accumulation
19 new · 16 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (19 new · 60 increased · 35 reduced · 16 closed · 5 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 135 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Jul 10, 2026Nagendran SukumarPresident and Head of R&DDisposed · Open-market sale200,000$6.24↗
Jun 1, 2026Long Alison SdirectorAcquired · Grant / award21,335—↗
Jun 1, 2026Long Alison SdirectorAcquired · Grant / award42,671Stock Option (right to buy)—↗
Jun 1, 2026Sepp-Lorenzino LauradirectorAcquired · Grant / award21,335—↗
Jun 1, 2026Sepp-Lorenzino LauradirectorAcquired · Grant / award42,671Stock Option (right to buy)—↗
Jun 1, 2026Stalfort SeandirectorAcquired · Grant / award21,335—↗
Jun 1, 2026Stalfort SeandirectorAcquired · Grant / award42,671Stock Option (right to buy)—↗
Jun 1, 2026DONENBERG PHILIP BdirectorAcquired · Grant / award21,335—↗
Jun 1, 2026DONENBERG PHILIP BdirectorAcquired · Grant / award42,671Stock Option (right to buy)—↗
Apr 10, 2026Nagendran SukumarPresident and Head of R&DAcquired · Option exercise19,021$1.71↗
Apr 10, 2026Nagendran SukumarPresident and Head of R&DDisposed · Open-market sale200,000$4.46↗
Apr 10, 2026Nagendran SukumarPresident and Head of R&DDisposed · Option exercise19,021Employee Stock Option (right to buy)—↗
Feb 4, 2026Alam KamranCHIEF FINANCIAL OFFICERDisposed · Open-market sale1,655$4.52↗
Jan 26, 2026Alam KamranCHIEF FINANCIAL OFFICERDisposed · Open-market sale23,849$4.61↗
Jan 26, 2026Nagendran SukumarPresident and Head of R&DDisposed · Open-market sale26,918$4.61↗
Jan 26, 2026Nolan Sean P.Chief Executive OfficerDisposed · Open-market sale41,312$4.61↗
Jan 23, 2026Alam KamranCHIEF FINANCIAL OFFICERDisposed · Open-market sale78,968$4.75↗
Jan 23, 2026Nagendran SukumarPresident and Head of R&DDisposed · Open-market sale89,132$4.75↗
Jan 23, 2026Nolan Sean P.Chief Executive OfficerDisposed · Open-market sale136,789$4.75↗
Jan 12, 2026Alam KamranCHIEF FINANCIAL OFFICERAcquired · Grant / award359,000—↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Taysha Gene Therapies do institutions hold?

13F filers reported holding 39.2% of Taysha Gene Therapies' shares as of Sep 30, 2026, across 135 filers.

How many 13F filers hold Taysha Gene Therapies?

Taysha Gene Therapies was held by 135 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.